Slide 1: Bioventus: Innovations For Active Healing
@ bioventus Innovations For Active Healing
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matter
Slide 3: Q2 2021 Results
on} bioventus’ | Q2 2021 Results
Slide 4: CEO Commentary on Q2 Results
“ Bioventus delivered strong second quarter results, driven by our team's ability to build upon the momentum we saw exiting the first quarter. We achieved significant sequential quarterly growth and year over year growth while also obtaining double digit organic growth in comparison to Q2 2019 for l
Slide 5: Q2 Revenue & Guidance Update
Q2 Revenue & Guidance update Full Year 2021 Revenue Guidance Total Q2 2021 Revenue +89% y.o.y. +26%-29% y.o.y. $109.8M (+29% compared to Q2 2019) $405-415M (+19%-22% compared to 2019) Organic Revenue Growth* Organic Revenue Growth* +69% y.o.y. +16%-18% y.o.y. (+15% compared to Q2 2019) (+10%-12% com
Slide 6: Revenue Breakdown
Revenue Breakdown Pain Treatments & Joint Preservation Bone Graft Substitutes Revenues + 96% y.o.y. Revenues +84% y.o.y. Q2 2021: $56.7M Q2 2021: $20.6M Q2 2020: $28.9M Q2 2020: $11.2M (+22% compared to Q2 2019) (+59% compared to Q2 2019) Restorative Therapies Revenues +81% y.o.y. Q2 2021: $32.5M Q2
Slide 7: Bioventus News
Bioventus News On April 27, 2021, the Company made the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance. On June 24, 2021, the Company announced a minority investment in Vaporox, a developer of a highly innovative diabetic foot ulcer wound healing therapy. On Ju
Slide 8: Bioventus: Innovations For Active Healing
@ bioventus Innovations For Active Healing